DiaMedica has reached 200 stroke trial patients. Could its next two readouts change DM199’s future?
DiaMedica approaches key DM199 readouts in fetal growth restriction and stroke. See how trial design, regulatory hurdles and cash runway intersect.
Pharma & Biotech